Why Azenta’s latest quarter is drawing attention

Azenta (AZTA) has come under pressure after its second quarter report, which combined a US$149,083,000 goodwill and intangible asset impairment with a wider net loss, prompting investors to reassess the stock.

The earnings report and US$149.1m impairment have clearly shifted sentiment, with the 7 day share price return of negative 24.42% feeding into a year to date share price return of negative 44.38% and a 5 year total shareholder return of negative 79.21% that points to fading momentum.

If Azenta’s recent swing has you reassessing your watchlist, it can help to compare against other high growth themes using a focused stock screener such as 35 healthcare AI stocks

With Azenta now trading at US$18.57 and sitting at a 36% discount to one estimate of intrinsic value and roughly 45% below one analyst price target, is this selloff an opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 47.5% Undervalued

Azenta’s most followed narrative pegs fair value at $35.40, which is well above the last close of $18.57 and frames the recent selloff very differently from the market.

The ongoing trend of life sciences digitization and automation is reflected in Azenta's improved operational execution and introduction of more automated solutions, these efficiency gains, alongside investments in R&D and product management, are producing significant gross margin and EBITDA margin expansion, pointing to further net margin improvements with scale.

Curious what is sitting behind that fair value gap? The narrative leans heavily on future revenue expansion, higher margins and a valuation multiple that assumes those targets stick.

Based on a discount rate of 7.88%, this narrative concludes that Azenta’s future cash generation justifies a fair value of $35.40, compared with the current price of $18.57. The difference between those two numbers is what underpins the view that the stock is 47.5% undervalued, even after factoring in execution risks and more conservative P/E assumptions than before.

Result: Fair Value of $35.40 (UNDERVALUED)

However, this depends on budgets and demand holding up, since delayed equipment orders and weaker gene synthesis and Sanger sequencing revenue could quickly challenge that undervalued story.

Next Steps

Sentiment in the article so far may feel cautious, so this is a good moment to move quickly, review the full picture, and shape your own view with the 3 key rewards.

Looking for more investment ideas?

If Azenta has you rethinking your approach, do not stop here. Use targeted screeners to quickly surface fresh ideas that fit what you are actually looking for.

• Spot potential value opportunities early by scanning a focused set of screener containing 23 high quality undiscovered gems that many investors may be overlooking.
• Prioritise resilience by filtering for 72 resilient stocks with low risk scores that score well on key risk metrics and business stability checks.
• Zero in on quality by reviewing a solid balance sheet and fundamentals stocks screener (44 results) to find companies with cleaner finances supporting their operations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.